APLS

Apellis Pharmaceuticals Stock Analysis

AI Rating

Good
  • Quality6/10
  • Growth↑ 6/10
  • Momentum↑ 5/10
Apellis Pharmaceuticals sales and earnings growth
APLS Growth
Good
  • Revenue Y/Y↑ 42.11%
  • EPS Y/Y↑ 117.33%
  • FCF Y/Y↑ 138.27%
Apellis Pharmaceuticals gross and profit margin trends
APLS Profitability
Good
  • Gross margin ↑ 88.80%
  • EPS margin↓ 4.40%
  • ROIC↓ 12.30%
Apellis Pharmaceuticals net debt vs free cash flow
APLS Risk
Great
  • Debt / Equity↓ 1.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ 2.0

Apellis Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗